NIPH Clinical Trials Search

UMIN ID: C000000037

Registered date:05/08/2005

A Multicenter Randomized Controlled Trial to Evaluate the Effect of Adjuvant Chemotherapy using Gemcitabine After Resection of Pancreatic Cancer

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedresectable pancreatic cancer
Date of first enrollment2002/04/01
Target sample size100
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)adjuvant systemic chemotherapy with gemcitabine 1000mg/m2 IV on days 1, 8, 15 every 28 days x 3 courses observation


Primary Outcomesurvival time, recurrence rate
Secondary Outcomeadverse effect

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximum75years-old
GenderMale and Female
Include criteria
Exclude criteriainterstitial pneumonia, pulmonary fibrosis intractable pleural effusion distant metastasis other active cancers apparent infection sever postoperative complications active peptic ulcer episode of myocardial infarction within three months mental disorders pregnacy or patient's hope to be pregnant

Related Information


public contact
Name Tomoo Kosuge
Address Japan
Telephone 03-3542-2511
Affiliation Office of the Study Group for Adjuvant Chemotherapy of Pancreatic Cancer National Cancer Center Hospital, HBP Surgery Division
scientific contact
Name Tomoo Kosuge
Address 5-1-1, Tsukiji, Chuo-ku, Tokyo Japan
Telephone 03-3542-2511
Affiliation National Cancer Center Hospital HBP Surgery Division